Mariano Andrés

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2499958/publications.pdf

Version: 2024-02-01

142 papers 2,252 citations

304743 22 h-index 254184 43 g-index

148 all docs 148 docs citations

times ranked

148

3339 citing authors

#	Article	IF	CITATIONS
1	Agreement Among Multiple Observers on Crystal Identification by Synovial Fluid Microscopy. Arthritis Care and Research, 2023, 75, 682-688.	3.4	8
2	Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors. Annals of the Rheumatic Diseases, 2022, 81, e131-e131.	0.9	23
3	Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland. Annals of the Rheumatic Diseases, 2022, 81, e124-e124.	0.9	3
4	Riesgo de fracturas vertebrales dorsales osteoporóticas en pacientes con gota. ReumatologÃa ClÃnica, 2022, 18, 279-285.	0.5	1
5	Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction. Arthritis Care and Research, 2022, 74, 1649-1658.	3.4	23
6	Male pituitary–gonadal axis dysfunction in postâ€acute COVIDâ€19 syndrome—Prevalence and associated factors: A Mediterranean case series. Clinical Endocrinology, 2022, 96, 353-362.	2.4	24
7	A small dose of intraarticular triamcinolone plus mepivacaine provides a rapid and sustained relief for gout flares. ReumatologÃa ClÃnica, 2022, 18, 129-130.	0.5	0
8	Dietary supplements for chronic gout. The Cochrane Library, 2022, 2022, CD010156.	2.8	1
9	Vascular deposition of monosodium urate crystals in gout: analysis of cadaveric tissue by dualâ€energy computed tomography and compensated polarizing light microscopy. Arthritis and Rheumatology, 2022, 74, 1295-1296.	5.6	4
10	A small dose of intraarticular triamcinolone plus mepivacaine provides a rapid and sustained relief for gout flares. ReumatologÃa ClÃnica (English Edition), 2022, 18, 129-130.	0.3	0
11	Birefringent crystals deposition and inflammasome expression in human atheroma plaques by levels of uricemia. Joint Bone Spine, 2022, 89, 105423.	1.6	3
12	Case series of acute arthritis during COVID-19 admission. Annals of the Rheumatic Diseases, 2021, 80, e58-e58.	0.9	53
13	Response to: ‴Comparative analysis of synovial inflammation after SARS-CoV-2 infection' by Alivernini <i>et al</i> . Annals of the Rheumatic Diseases, 2021, 80, e92-e92.	0.9	2
14	Acute arthritis following SARSâ€CoVâ€2 infection. Journal of Medical Virology, 2021, 93, 661-661.	5.0	9
15	Crystal deposition measured with dual-energy computed tomography: association with mortality and cardiovascular risks in gout. Rheumatology, 2021, 60, 4855-4860.	1.9	22
16	An integrated emergency department/hospital at home model in mild COVID-19 pneumonia: feasibility and outcomes after discharge from the emergency department. Internal and Emergency Medicine, 2021, 16, 1673-1682.	2.0	15
17	Gouty Involvement of Foot and Ankle: Beyond Flares. ReumatologÃa ClÃnica, 2021, 17, 106-112.	0.5	2
18	Gouty Involvement of Foot and Ankle: Beyond Flares. ReumatologÃa ClÃnica (English Edition), 2021, 17, 106-112.	0.3	1

#	Article	IF	CITATIONS
19	Fatality and risk features for prognosis in COVID-19 according to the care approach $\hat{a} \in \text{``a retrospective }$ cohort study. PLoS ONE, 2021, 16, e0248869.	2.5	12
20	Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. Journal of Infection, 2021, 82, 378-383.	3.3	456
21	Human papilloma virus screening: evaluation of testing and surveillance in rheumatoid arthritis, psoriatic arthritis and systemic lupus erythematosus. ReumatologÃa ClÃnica (English Edition), 2021, 17, 494-498.	0.3	0
22	The COVID-GRAM Tool for Patients Hospitalized With COVID-19 in Europe. JAMA Internal Medicine, 2021, 181, 1000-1001.	5.1	14
23	Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?. Rheumatology, 2021, 60, 5329-5336.	1.9	4
24	Mediumâ€term serostatus in Spanish case series recovered from SARSâ€CoVâ€2 infection. Journal of Medical Virology, 2021, 93, 6030-6039.	5.0	1
25	Plasma ACE2 species are differentially altered in COVIDâ€19 patients. FASEB Journal, 2021, 35, e21745.	0.5	18
26	Urate levels and clearance in renal patients under peritoneal dialysis. Nucleosides, Nucleotides and Nucleic Acids, 2021, 40, 720-731.	1.1	2
27	Clinical Frailty Score vs Hospital Frailty Risk Score for predicting mortality and other adverse outcome in hospitalised patients with COVIDâ€19: Spanish case series. International Journal of Clinical Practice, 2021, 75, e14599.	1.7	21
28	Risk of osteoporotic thoracic vertebral fractures in patients with gout. Reumatolog \tilde{A} a $Cl\tilde{A}$ nica (English Edition), 2021, , .	0.3	1
29	Aplicación de escalas pronósticas de gravedad en la neumonÃa por SARS-CoV-2. Medicina ClÃnica, 2021, 157, 99-105.	0.6	6
30	Application of validated severity scores for pneumonia caused by SARS-CoV-2. Medicina ClÃnica (English Edition), 2021, 157, 99-105.	0.2	9
31	Serum Urate Levels of Hemodialyzed Renal Patients Revisited. Journal of Clinical Rheumatology, 2021, 27, e362-e366.	0.9	6
32	Cribado del virus de papiloma humano: evaluación de grado de vigilancia en artritis reumatoide, artritis psoriásica y lupus eritematoso sistémico. ReumatologÃa ClÃnica, 2021, 17, 494-498.	0.5	5
33	Sonographic Tophi and Inflammation Are Associated With Carotid Atheroma Plaques in Gout. Frontiers in Medicine, 2021, 8, 795984.	2.6	10
34	Role of Carotid Ultrasound and Systematic Coronary Risk Evaluation Charts for the Cardiovascular Risk Stratification of Patients with Psoriatic Arthritis. Journal of Rheumatology, 2020, 47, 682-689.	2.0	7
35	Gout Management as Part of Secondary Cardiovascular Prevention: Comment on the Article by Stamp et al. Arthritis and Rheumatology, 2020, 72, 377-377.	5. 6	0
36	Progresses in the imaging of calcium pyrophosphate crystal disease. Current Opinion in Rheumatology, 2020, 32, 140-145.	4.3	5

#	Article	IF	Citations
37	Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study. Journal of Autoimmunity, 2020, 114, 102523.	6.5	51
38	Gout Is Prevalent but Under-Registered Among Patients With Cardiovascular Events: A Field Study. Frontiers in Medicine, 2020, 7, 560.	2.6	9
39	Mixed Crystal Disease: A Tale of 2 Crystals. Journal of Rheumatology, 2020, 47, 1158-1159.	2.0	4
40	Gout. Journal of Clinical Rheumatology, 2020, 26, 208-212.	0.9	0
41	Hypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: A case series of 306 Mediterranean patients. International Journal of Infectious Diseases, 2020, 100, 449-454.	3.3	55
42	Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality. Lupus, 2020, 29, 1556-1565.	1.6	19
43	Is Remission a Valid Target for Gout?. Journal of Rheumatology, 2020, 47, 4-5.	2.0	3
44	Persistence of Crystals in Stored Synovial Fluid Samples. Journal of Rheumatology, 2020, 47, 1416-1423.	2.0	8
45	Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus. Rheumatology, 2020, 59, 2544-2549.	1.9	30
46	Gout, Hyperuricemia, and Crystalâ€Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. Arthritis Care and Research, 2019, 71, 427-434.	3.4	73
47	Gouty arthritis mutilans: obvious but ignored on two occasions. Rheumatology, 2019, 59, 695.	1.9	1
48	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Annals of the Rheumatic Diseases, 2019, 78, 1592-1600.	0.9	72
49	Most needle-shaped calcium pyrophosphate crystals lack birefringence. Rheumatology, 2019, 58, 1095-1098.	1.9	12
50	Synovial fluid leukocyte count in asymptomatic hyperuricaemia with crystal deposition: a proof-of-concept study. Rheumatology, 2019, 58, 1104-1105.	1.9	7
51	OP0249â€ANTIPHOSPHOLIPID SYNDROME (APS) IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) LEADS TO A MOSEVERE DISEASE., 2019, , .	ORE	0
52	SAT0386â€PREVALENCE OF SUBCLINICAL CARDIOVASCULAR DISEASE IN PSORIATIC ARTHRITIS: A MULTICENT STUDY. , 2019, , .	RIC	0
53	SATO199 POLYAUTOIMMUNITY IN SYSTEMIC LUPUS ERYTHEMATOSUS. DATA FROM A LARGE SPANISH COHORT: SPANISH SOCIETY OF RHEUMATOLOGY REGISTRY OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (RELESSER), 2019, , .		0
54	AB0865â€GOUT IN HOSPITALISED PATIENTS FOR CARDIOVASCULAR DISEASES: PREVALENCE AND MANAGEMI STATUS., 2019, , .	ENT	0

#	Article	IF	CITATIONS
55	AB0473â€HYPOGAMMAGLOBULINEMIA AND INFECTIONS IN RHEUMATOLOGIC PATIENTS TREATED WITH RITUXIMAB., 2019,,.		0
56	SAT0441â€SKIN ADVERSE EVENTS WITH FEBUXOSTAT IN GOUT PATIENTSWITH PREVIOUS SKIN REACTIONS TALLOPURINOL. A MULTICENTRE DESCRIPTIVE STUDY. , 2019, , .	O	1
57	SAT0442â€CALCIUM PYROPHOSPHATE CRYSTAL ARTHRITIS DURING HOSPITALIZATIONS: A PROSPECTIVE, CRYSTAL-PROVEN CASE SERIES. , 2019, , .		0
58	SP0062â€CARDIOVASCULAR MORBIDITY AND GOUT – FROM EPIDEMIOLOGY TO THERAPY. , 2019, , .		0
59	FRIO692â€34. REHABILITATION HUMAN PAPILLOMA VIRUSSCREENING AND CHRONIC INFLAMMATORY ARTHRAN AUDIT., 2019, , .	elTIS:	0
60	Hyperuricemia and the Silent Deposition of Monosodium Urate Crystals., 2019,, 1-7.		1
61	Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature. ReumatologÃa ClÃnica, 2019, 15, 34-42.	0.5	6
62	Therapy for CPPD: Options and Evidence. Current Rheumatology Reports, 2018, 20, 31.	4.7	24
63	Managing Gout in the Patient with Renal Impairment. Drugs and Aging, 2018, 35, 263-273.	2.7	10
64	Interleukin-6 pathway blockade as an option for managing refractory cases of crystal arthritis: Two cases report. Joint Bone Spine, 2018, 85, 377-378.	1.6	9
65	Improvement in Diagnosis and Treat-to-Target Management of Hyperuricemia in Gout: Results from the GEMA-2 Transversal Study on Practice. Rheumatology and Therapy, 2018, 5, 243-253.	2.3	25
66	Urate crystals and inflammation. Cardiovascular impact of gout. International Journal of Cardiology, 2018, 271, 295.	1.7	0
67	Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort. Arthritis Research and Therapy, 2018, 20, 53.	3.5	8
68	Diagnóstico y tratamiento de la gota. Medicina ClÃnica, 2017, 148, 271-276.	0.6	11
69	Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. Annals of the Rheumatic Diseases, 2017, 76, 1263-1268.	0.9	38
70	Clinical Images: Hematoidin in Synovial Fluid. Arthritis and Rheumatology, 2017, 69, 836-836.	5.6	1
71	Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2017, 47, 38-45.	3.4	117
72	Gout: Diagnosis and treatment. Medicina ClÃnica (English Edition), 2017, 148, 271-276.	0.2	3

#	Article	IF	CITATIONS
73	Bruton's Tyrosine Kinase Inhibitors Could Induce Rheumatoid Arthritisâ 'Like Manifestations: Comment on the Article by Nyhoff et al. Arthritis and Rheumatology, 2017, 69, 475-475.	5.6	3
74	Inflammatory status and uricaemia determine HDL-cholesterol levels in hypertensive adults over 65: an analysis of the FAPRES register. Rheumatology International, 2017, 37, 941-948.	3.0	1
75	Severe gout: Strategies and innovations for effective management. Joint Bone Spine, 2017, 84, 541-546.	1.6	18
76	GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. Annals of the Rheumatic Diseases, 2017, 76, 869-877.	0.9	114
77	AB0890â€Systemic lupus erythematosus and gout: really an unusual association?., 2017,,.		O
78	THU0441â€Synovial fluid leukocyte count and its association with crystal deposition in asymptomatic hyperuricemia: a preliminary report., 2017,,.		0
79	FRI0571â€Osteoporosis and breast cancer: can frax-based risk factors accurately predict further fractures at this setting?. , 2017, , .		0
80	THU0406â€Serum uric acid lowering treatment appears unnecessary during hemodialysis. , 2017, , .		O
81	THU0437 Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort., 2017,,.		0
82	THU0464â€A genome-wide association study of gout in people of european ancestry. , 2017, , .		0
83	FRI0570â€Osteoporosis and breast cancer: outcomes at a specialized osteoporosis clinic following a structured assessment. , 2017, , .		O
84	AB0362â€Serum Lipid Level Changes Associated with Tocilizumab Treatment: Our Experience in Two University Hospitals:. Annals of the Rheumatic Diseases, 2016, 75, 1027.2-1027.	0.9	0
85	SAT0628-HPRâ€Cardiovascular Risk Assessment in Inflammatory Arthritis Patients in A Nurse-led Clinic and Supported by Ultrasonography. Annals of the Rheumatic Diseases, 2016, 75, 1291.1-1291.	0.9	O
86	Current advances in therapies for calcium pyrophosphate crystal arthritis. Current Opinion in Rheumatology, 2016, 28, 140-144.	4.3	8
87	Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia: An Exploratory Study. Arthritis and Rheumatology, 2016, 68, 1531-1539.	5.6	74
88	Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al. Arthritis and Rheumatology, 2016, 68, 2563-2564.	5.6	9
89	THU0494â€Skin Events with Febuxostat in Gout Patients with Previous Skin Reactions To Allopurinol. A Retrospective Review:. Annals of the Rheumatic Diseases, 2016, 75, 370.3-371.	0.9	1
90	Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry. Rheumatology, 2016, 55, 1243-1250.	1.9	28

#	Article	IF	Citations
91	Gout mimicking rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2016, 45, e28.	3.4	1
92	Centre-related variability in hospital admissions of patients with spondyloarthritis. Rheumatology International, 2016, 36, 1301-1308.	3.0	0
93	Centre characteristics determine ambulatory care and referrals in patients with spondyloarthritis. Rheumatology International, 2016, 36, 1515-1523.	3.0	1
94	THU0508â€Improvement in Treat To Target Serum Urate Levels: Results from A Comparison between The Gema and The Gema-II Audits: Table 1. Annals of the Rheumatic Diseases, 2016, 75, 376.1-376.	0.9	0
95	THU0518â€New Cardiovascular Risk Factors Screening in Patients with Gout. Annals of the Rheumatic Diseases, 2016, 75, 379.2-379.	0.9	0
96	THU0517â€Women with Gout Show A Poorer Cardiovascular Profile after Structured Assessment. Annals of the Rheumatic Diseases, 2016, 75, 379.1-379.	0.9	0
97	AB0815â€Intraarticular Triamcinolone plus Mepivacaine Provides A Rapid and Sustained Relief for Acute Gouty Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1182.2-1182.	0.9	1
98	FRI0022â€Inflammatory Status and Serum Uric Acid Levels Determine High-Density Lipoproteinâ€"Cholesterol Levels in A Non-Rheumatic Population: Table 1. Annals of the Rheumatic Diseases, 2016, 75, 433.2-433.	0.9	0
99	Primary Tuberculosis Infection in Patients Treated With Tumor Necrosis Factor-alpha Antagonists and a Negative Initial Screening. ReumatologÃa ClÃnica (English Edition), 2016, 12, 81-84.	0.3	1
100	Gout: optimizing treatment to achieve a disease cure. Therapeutic Advances in Chronic Disease, 2016, 7, 135-144.	2.5	27
101	Primoinfección tuberculosa en pacientes con anti-TNF-α y cribado inicial negativo. ReumatologÃa ClÃnica, 2016, 12, 81-84.	0.5	4
102	FRI0325â€Silent Deposit of MSU Crystals Associates with a More Severe Coronary Calcification in Asymptomatic Hyperuricemic Patients with Acute Coronary Syndrome. Annals of the Rheumatic Diseases, 2015, 74, 542.1-542.	0.9	0
103	FRIO104â€Ultrasonographic Synovitis in Patients with Rheumatoid Arthritis and Optimization of Subcutaneous Biologic Drugs. Annals of the Rheumatic Diseases, 2015, 74, 457.1-457.	0.9	0
104	OPO140-HPRâ€The Role of a Nurse-Clinic in the Assessment and Prevention of Cardio-Vascular Risk. Annals of the Rheumatic Diseases, 2015, 74, 121.3-121.	0.9	2
105	AB1139â€Centre Characteristics Determine Ambulatory Care and Referrals in Patients with Spondyloarthritis:. Annals of the Rheumatic Diseases, 2015, 74, 1283.1-1283.	0.9	0
106	SATO328â€Uric Acid Enhances Monosodium Urate Induced Pro-Inflammatory Response in Gouty Patients: A Basic and Translational Research Study. Annals of the Rheumatic Diseases, 2015, 74, 777.2-778.	0.9	3
107	AB1208â€Educational Needs for Young Rheumatologists in Spain. Annals of the Rheumatic Diseases, 2015, 74, 1307.2-1307.	0.9	0
108	AB0924â€Echocardiography Findings in Asymptomatic Hyperuricemic Patients with Silent Deposit of MSU Crystals:. Annals of the Rheumatic Diseases, 2015, 74, 1209.2-1209.	0.9	0

#	Article	IF	CITATIONS
109	SAT0311â€The Shape of Calcium Pyrophosphate Crystals Determines their Intensity of Birefringence. Annals of the Rheumatic Diseases, 2015, 74, 770.3-771.	0.9	O
110	FRIO327â€Febuxostat Appears Effective and Safe in Gout Patients with Severe Chronic Kidney Disease:. Annals of the Rheumatic Diseases, 2015, 74, 542.3-543.	0.9	1
111	Gout and the heart: beyond comorbidities. International Journal of Clinical Rheumatology, 2015, 10, 329-334.	0.3	0
112	MRI myositis sine myositis: the importance of the histopathology. Rheumatology, 2015, 54, 76-76.	1.9	4
113	Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease?. Arthritis Research and Therapy, 2015, 17, 89.	3.5	6
114	Comment on: The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study. Rheumatology, 2015, 54, 1328-1329.	1.9	2
115	Mechanisms of crystal formation in goutâ€"a structural approach. Nature Reviews Rheumatology, 2015, 11, 725-730.	8.0	79
116	Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: Ascertaining the Efficacy of Treatment Matters. American Journal of Medicine, 2015, 128, e41-e42.	1.5	1
117	Treatment Target and Followup Measures for Patients with Gout: A Systematic Literature Review. Journal of rheumatology Supplement, The, 2014, 92, 55-62.	2.2	7
118	Dietary supplements for chronic gout. The Cochrane Library, 2014, , CD010156.	2.8	18
119	Interleukin-1 inhibitors for acute gout. The Cochrane Library, 2014, 2014, CD009993.	2.8	23
120	Rapid crystal dissolution in gout: is it feasible and advisable?. International Journal of Clinical Rheumatology, 2014, 9, 395-401.	0.3	2
121	Dealing with refractoriness in obstetric primary antiphospholipid syndromeâ€"often not a matter of success. Lupus, 2014, 23, 964-965.	1.6	1
122	Pigmented villonodular synovitis diagnostic delay due to coexistence with ankylosing spondylitis. ReumatologÃa ClÃnica, 2014, 10, 270-271.	0.5	2
123	Diagnostic Value of Clinical, Laboratory, and Imaging Findings in Patients with a Clinical Suspicion of Gout: A Systematic Literature Review. Journal of rheumatology Supplement, The, 2014, 92, 3-8.	2.2	16
124	Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Annals of the Rheumatic Diseases, 2014, 73, 328-335.	0.9	222
125	THU0493â€Association of the Toll-Like Receptor 4 (TLR4) Gene with Gout. Annals of the Rheumatic Diseases, 2014, 73, 354.1-354.	0.9	2
126	AB0706â€Centre-Related Features Determine Variability of Hospital Admissions of Patients with Spondyloarthritides in Spain: Table 1 Annals of the Rheumatic Diseases, 2014, 73, 1037.3-1037.	0.9	1

#	Article	IF	Citations
127	Lupus nephritis: a 15â€year multiâ€centre experience in the UK. Lupus, 2013, 22, 328-332.	1.6	24
128	Anakinra for a refractory case of intermittent hydrarthrosis with a TRAPS-related gene mutation. Annals of the Rheumatic Diseases, 2013, 72, 155-155.	0.9	14
129	Criteria for Gout Diagnosis?. Journal of Rheumatology, 2013, 40, 356-358.	2.0	12
130	Back Pain Due to Lumbar Gouty Flare — A Prospective Diagnosis. Journal of Rheumatology, 2013, 40, 1459-1460.	2.0	2
131	Gout treatment: should we aim for rapid crystal dissolution?. Annals of the Rheumatic Diseases, 2013, 72, 635-637.	0.9	22
132	OPO104â€Hypouricemia due to high urate renal excretion in septic systemic inflammatory response syndrome. Annals of the Rheumatic Diseases, 2013, 71, 88.1-88.	0.9	0
133	Marked improvement of lung rheumatoid nodules after treatment with tocilizumab. Rheumatology, 2012, 51, 1132-1134.	1.9	24
134	Methotrexate Is an Option for Patients With Refractory Calcium Pyrophosphate Crystal Arthritis. Journal of Clinical Rheumatology, 2012, 18, 234-236.	0.9	24
135	LÃ"pre lépromateuse révélant une polyarthrite aiguë chez un immigrant colombien résidant en Espagn Revue Du Rhumatisme (Edition Francaise), 2012, 79, 178-179.	e. _{0.0}	0
136	Lepromatous leprosy presenting as an acute polyarthritis in a Colombian immigrant in Spain. Joint Bone Spine, 2012, 79, 203-204.	1.6	2
137	Calcium pyrophosphate crystal deposition. International Journal of Clinical Rheumatology, 2011, 6, 677-688.	0.3	3
138	Synovial fluid analysis for crystals. Current Opinion in Rheumatology, 2011, 23, 161-169.	4.3	62
139	No hepatitis B reactivation in a patient with refractory antisynthetase syndrome successfully treated with rituximab. Joint Bone Spine, 2011, 78, 653-654.	1.6	6
140	Small muscle myositis in a patient with systemic lupus erythematosus successfully treated with rituximab. Lupus, 2011, 20, 1340-1341.	1.6	2
141	Clinical Images: Osteochondroma leading to Snapping Scapula Syndrome. Arthritis and Rheumatism, 2010, 62, 1838-1838.	6.7	2
142	Tratamiento de la enfermedad por cristales de pirofosfato cálcico. Seminarios De La Fundaciâ^šâ‰¥n Espaâ^šÂ±ola De Reumatologâ^šâ‰a, 2010, 11, 159-161.	0.1	0